DEC 05, 2019 2:07 AM PST

Catching drug-resistant HIV mutants with next generation sequencing

WRITTEN BY: Tara Fernandez

Human immunodeficiency virus (HIV)-positive individuals are treated with antiretroviral therapies to reduce the amount of circulating virus, restore their immune functions and prevent disease transmission. There are around 30 different anti-HIV drugs currently available, with most antiretroviral regimens including a cocktail of 2 or more of these drugs. 

In the best-case scenario, taking antiretroviral drugs daily typically sees patients reaching undetectable levels of virus within 3 to 6 months.

The virus, however, can get the upper hand with its ability to mutate and become completely immune to the virus-killing action of these therapeutics. HIV is a retrovirus and proliferates rapidly, replicating its genome with an enzyme called reverse transcriptase. This enzyme is known for its inability to correct errors made during the replication process, which results in an extremely high mutation rate.

This is of particular concern to the global community, with the WHO estimating that in 2018, 23.3 million people were routinely receiving antiretroviral treatment. Rapidly growing levels of resistance to antiviral drugs could significantly undermine the progress made in providing HIV-positive patients with life-saving medical interventions.

Recently, the U.S. Food and Drug Administration authorized the marketing of a new test to detect the presence of drug-resistant HIV. This testing platform makes use of powerful DNA sequencing technology, known as next-generation sequencing, or NGS. 

Unlike early DNA sequencing methods, NGS is incredibly fast, sequencing an entire human genome with unparalleled precision, at a fraction of the cost and in just 24 hours.

Conventional methods of monitoring the efficacy of antiretroviral drugs involve keeping track of the amount of circulating virus in the patient’s bloodstream. A rising viral load, in spite of ongoing therapy, points to the occurrence of drug-resistant mutations and requires a change in regimen to suppress viral proliferation.

The director of the FDA’s Center for Biologics Evaluation and Research, Peter Marks, believes NGS technology can be leveraged for more personalized treatment plans.

“Today’s authorization can help health care providers better tailor drug treatment for patients who are beginning antiviral therapy and also for those who have developed resistance to HIV drugs by helping to identify mutations in the HIV-1 virus that can impact the effectiveness of certain drugs,” said Marks at a recent press conference.

The new screening platform, called the Sentosa SQ HIV Genotyping Assay, is a quick, reliable and fully automated system, boasting highly sensitive detection with minimal hands-on time. The technology was developed by Vela Diagnostics, with its global headquarters located in Singapore, and is a big leap forward in the company’s mission to be at the forefront of global molecular diagnostics.

 

Sources: World Health Organization, FDA, Vela Diagnostics.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
APR 07, 2020
Clinical & Molecular DX
Computers Predict Diabetes with 94.9 Percent Accuracy
APR 07, 2020
Computers Predict Diabetes with 94.9 Percent Accuracy
"Currently we do not have sufficient methods for predicting which generally healthy individuals will develop diabet ...
APR 22, 2020
Drug Discovery & Development
Only 3% of COVID-19 Antibody Tests Approved by FDA
APR 22, 2020
Only 3% of COVID-19 Antibody Tests Approved by FDA
So far, only 3% of at least 90 COVID-19 antibody tests in the US have been approved by the Food and Drug Administration ...
JUN 16, 2020
Clinical & Molecular DX
Don't Sweat It! New Tech Monitors Health With a Single Drop of Sweat.
JUN 16, 2020
Don't Sweat It! New Tech Monitors Health With a Single Drop of Sweat.
Looking for ways to cool off and beat the summer heat? Think twice before wiping that sweat off your brow. Every drop of ...
JUL 03, 2020
Cancer
Using Machine Learning to Further Classify Triple-Negative Breast Cancer
JUL 03, 2020
Using Machine Learning to Further Classify Triple-Negative Breast Cancer
One of the challenges of facing cancer researchers is coming up with a clearly defined classification system. Cancer is ...
JUL 14, 2020
Clinical & Molecular DX
The Smell of Rotten Fish Could Help Predict the Recovery of Unresponsive Patients
JUL 14, 2020
The Smell of Rotten Fish Could Help Predict the Recovery of Unresponsive Patients
A study published in the journal Nature provides new evidence supporting an unconventional test to map recovery paths of ...
AUG 04, 2020
Cardiology
Does Chronic Anxiety Affect Heart Health?
AUG 04, 2020
Does Chronic Anxiety Affect Heart Health?
Anxiety is something that is talked about far more often nowadays. In recent years, it has even been linked to a variety ...
Loading Comments...